二甲双胍降低2型糖尿病患者尿单核细胞趋化蛋白-1的排泄

Effects of metformin on urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics

目的观察二甲双胍对2型糖尿病(DM)患者尿单核细胞趋化蛋白-1(MCP-1)排泄的影响,探讨二甲双胍对2型糖尿病的保护作用。方法对50例初诊的2型糖尿病患者给予二甲双胍治疗12周,观察12周前后相关代谢指标及尿MCP-1排泄的变化,同期选择30例体检健康人群作对照分析。结果 (1)2型糖尿病患者空腹血糖,餐后2 h血糖、糖化血红蛋白、血压、体重指数、腰臀比及尿MCP-1水平较正常对照组明显升高(P<0.01),二甲双胍治疗12周后各组以上指标均较基线水平明显降低(P<0.01或P<0.05);(2)糖尿病患者尿MCP-1肌酐比与空腹血糖,糖化血红蛋白,血压均呈正相关。结论 2型糖尿病患者体内存在一定的炎症反应,二甲双胍在降低血糖的同时具有一定的降压,抗炎作用。

Objective To observe the effect of metformin on urinary Monocyte chemoattractant protein-1 （ MCP-1 ） excretion in type 2 diabetics and to explore the mechanisms. Methods Fifty type 2 diabetics were enrolled in the study and then were administered mefformin for 12 weeks. We examined the clinical metabolic index and urinary MCP-1 excretion at baseline and the 12th week. Results Indexes including fasting blood glucose ,2-hour postprandial blood glucose, glycated haemoglobin A1 c, blood pressure, body mass index, whist-hip ratio and urinary MCP-1 to urinary creatinine ratio in type 2 diabetic patients increased significantly compared with those of the normal control group at basal level （P 〈 0.01 ）. The parameters mentioned above were markedly decreased following 12-week metformin administration. Urinary MCP-1 to urinary creatinine ratio has positive correlations with fasting blood glucose and 2-hour postprandial blood glucose （ r = 0. 692, r = 0.615, P 〈 0.01 ）, respectively. Conclusion Inflammation may be implicated in type 2 diabetes. Mefformin not only could improve glyeemic control, but also could alleviate local renal inflammatory action.